Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review

被引:1
作者
Wang, Jian [1 ,2 ]
Xiao, Xiaoyue [3 ]
Dong, Xiaorong [1 ,2 ]
Wu, Gang [1 ,2 ]
Wang, Xinghua [4 ]
Zhang, Ruiguang [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Inst Radiat Oncol, Tongji Med Coll, Wuhan, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiovasc Surg, Wuhan, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Ophthalmol, Wuhan, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
non-small cell lung cancer; immune-related adverse events; optic neuropathy PD-1; sintilimab; IMMUNOTHERAPY-RELATED TOXICITIES; NIVOLUMAB; MANAGEMENT; DOCETAXEL;
D O I
10.3389/fonc.2022.931074
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Anti-PD-1/PD-L1 immunotherapy reactivates T-cell activity to boost the antitumor effect and may trigger autoimmune toxicity in various organ systems involving eyeball and periocular structures at the same time. The rarity of ocular immune-related adverse events should not prevent us from paying attention to this issue because of the bad consequences of visual impairment. This is the first case report of anti-PD-1 sintilimab-induced bilateral optic neuropathy in a 76-year-old man with squamous non-small cell lung cancer (NSCLC). The patient presented with sudden vision blurring without pain in both eyes after three therapeutic cycles of sintilimab plus chemotherapy. Based on the ophthalmic examination, laboratory, and radiological results, our patient was diagnosed with optic neuropathy complication secondary to anti-PD-1 sintilimab treatment. Consequently, sintilimab was held and systemic steroids were administered. The follow-up review showed that the vision recovered and the size of the primary tumor continued to decrease with the response assessment as the partial response. In conclusion, this case report suggested that patients with NSCLC undergoing anti-PD-1/PD-L1 therapy should be closely monitored for ophthalmic assessment and alert to the occurrence of sintilimab-induced optic neuropathy.
引用
收藏
页数:9
相关论文
共 39 条
  • [1] Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
    Bastacky, Melissa L.
    Wang, Hong
    Fortman, Dylan
    Rahman, Zahra
    Mascara, Gerard P.
    Brenner, Timothy
    Najjar, Yana G.
    Luke, Jason J.
    Kirkwood, John M.
    Zarour, Hassane M.
    Davar, Diwakar
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [2] Borghaei H, 2021, J CLIN ONCOL, V39, P723, DOI 10.1200/JCO.20.01605
  • [3] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
    Brahmer, Julie R.
    Lacchetti, Christina
    Schneider, Bryan J.
    Atkins, Michael B.
    Brassil, Kelly J.
    Caterino, Jeffrey M.
    Chau, Ian
    Ernstoff, Marc S.
    Gardner, Jennifer M.
    Ginex, Pamela
    Hallmeyer, Sigrun
    Chakrabarty, Jennifer Holter
    Leighl, Natasha B.
    Mammen, Jennifer S.
    McDermott, David F.
    Naing, Aung
    Nastoupil, Loretta J.
    Phillips, Tanyanika
    Porter, Laura D.
    Puzanov, Igor
    Reichner, Cristina A.
    Santomasso, Bianca D.
    Seigel, Carole
    Spira, Alexander
    Suarez-Almazor, Maria E.
    Wang, Yinghong
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Thompson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
  • [4] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population
    Brzezianska, Ewa
    Karbownik, Malgorzata
    Migdalska-Sek, Monika
    Pastuszak-Lewandoska, Dorota
    Wloch, Jan
    Lewinski, Andrzej
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) : 26 - 35
  • [5] Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
    Burke, Michael
    Rashdan, Sawsan
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
    Cortellini, Alessio
    Chiari, Rita
    Ricciuti, Biagio
    Metro, Giulio
    Perrone, Fabiana
    Tiseo, Marcello
    Bersanelli, Melissa
    Bordi, Paola
    Santini, Daniele
    Giusti, Raffaele
    Grassadonia, Antonino
    Di Marino, Pietro
    Tinari, Nicola
    De Tursi, Michele
    Zoratto, Federica
    Veltri, Enzo
    Malorgio, Francesco
    Garufi, Carlo
    Russano, Marco
    Anesi, Cecilia
    Zeppola, Tea
    Filetti, Marco
    Marchetti, Paolo
    Berardi, Rossana
    Rinaldi, Silvia
    Tudini, Marianna
    Silva, Rosa Rita
    Pireddu, Annagrazia
    Atzori, Francesco
    Iacono, Daniela
    Migliorino, Maria Rita
    Porzio, Gampiero
    Cannita, Katia
    Ficorella, Corrado
    Buti, Sebastiano
    [J]. CLINICAL LUNG CANCER, 2019, 20 (04) : 237 - +
  • [7] Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma
    Cybulska-Stopa, Bozena
    Zietek, Marcin
    Czarnecka, Anna M.
    Piejko, Karolina
    Dziura, Robert
    Galus, Lukasz
    Ziolkowska, Barbara
    Kieszko, Stanislaw
    Kempa-Kaminska, Natasza
    Calik, Jacek
    Seredynska, Joanna
    Gadek, Kamila
    Zemelka, Tomasz
    Teterycz, Pawel
    Kubiatowski, Tomasz
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2168 - 2174
  • [8] Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
    Daniello, Lea
    Elshiaty, Mariam
    Bozorgmehr, Farastuk
    Kuon, Jonas
    Kazdal, Daniel
    Schindler, Hannah
    Shah, Rajiv
    Volckmar, Anna-Lena
    Lusky, Fabienne
    Diekmann, Leonore
    Liersch, Stephan
    Faehling, Martin
    Muley, Thomas
    Kriegsmann, Mark
    Benesova, Karolina
    Stenzinger, Albrecht
    Thomas, Michael
    Christopoulos, Petros
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
    Das, Satya
    Johnson, Douglas B.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
  • [10] The changing landscape of optic neuritis: a narrative review
    De Lott, Lindsey B.
    Bennett, Jeffrey L.
    Costello, Fiona
    [J]. JOURNAL OF NEUROLOGY, 2022, 269 (01) : 111 - 124